Share on StockTwits

Synta Pharmaceuticals Corp. (NASDAQ:SNTA) released its earnings data on Wednesday. The company reported ($0.24) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.27) by $0.03, AnalystRatingsNetwork reports.

On a related note, analysts at MLV & Co
raised their price target on shares of Synta Pharmaceuticals Corp. from $6.00 to $6.50 in a research note on Friday, May 9th. They now have a “buy” rating on the stock. Two equities research analysts have rated the stock with a sell rating and two have issued a buy rating to the company. Synta Pharmaceuticals Corp. presently has a consensus rating of “Hold” and a consensus price target of $9.13.

Synta Pharmaceuticals Corp. (NASDAQ:SNTA) opened at 3.95 on Wednesday. Synta Pharmaceuticals Corp. has a 52-week low of $3.70 and a 52-week high of $7.30. The stock has a 50-day moving average of $4.20 and a 200-day moving average of $4.66. The company’s market cap is $345.9 million.

Synta Pharmaceuticals Corp. is a biopharmaceutical company. The Company is focused on discovering, developing, and commercializing small molecule drugs to severe the medical conditions of the patients with cancer and inflammatory diseases.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.